Stefano Perotti, Chairman of the board, he has degrees in Economics and Law. He has years of working experience in bank, mainly dealing with the financial market. More recently, he managed the treasuries of a few multinational corporations.
Sergio Decherchi, Senior Developer and co-founder, is a data scientist with a MD in electronics engineering and a Ph.D in machine learning with experience in software development and technology transfer. He develops algorithms (e.g. NanoShaper) for addressing computational chemistry problems.
Giovanni Bottegoni, Ph.D and co-founder, biotechnologist by training, Dr. Giovanni Bottegoni is a scientist and an entrepreneur. In 2006, he obtained his doctorate in medicinal chemistry from the University of Bologna then moved to the Scripps Research Institute (La Jolla, CA – USA) for his first post-doctoral experience. After two years, he joined the Istituto Italiano di Tecnologia (IIT), first as a postdoctoral fellow and eventually as a team leader at the Dept. of Drug Discovery and Development. His current scientific interests are in structure-based drug design and in silico polypharmacology. The longstanding aim of his research is to turn computer simulations into actionable knowledge for medicinal chemistry. He attended the XV ed. of the Master in International Healthcare Management Economics and Policy (MIHMEP) at Bocconi School of Management in Milan and graduated cum laudein February 2015. He also obtained a Certificate of Advanced Studies in Management of Biotech, Medtech and Pharma Ventures issued by the École Polytechnique Fédérale de Lausanne (EPFL, CH).
Andrea Cavalli, Prof. Ph.D and co-founder, is a medicinal chemist by training, Andrea has a long standing experience in molecular dynamics simulations and drug discovery. His first application of MD in drug discovery dates back to 1998. He then consolidated this at ETH-Zurich and SISSA-Trieste. He has been a pioneer in the development of protocols based on enhanced sampling (e.g. metadynamics, steered MD, etc.) for drug design. Currently, Andrea is Head of D3 Computation at IIT, and Prof. of Medicinal Chemistry at the University of Bologna.
Marco De Vivo, Ph.D, is a chemist by training, and is the director of the laboratory for Molecular Modeling and Drug Discovery at IIT. Before joining IIT, he was postdoc with M.L. Klein at UPenn, and then researcher at Rib-X Pharmaceutics, a spin-off biotech company from Yale University co-founded by Prof. T. A. Steitz and Prof. W. L. Jorgensen. He is an expert in integrating computational modeling and simulations with medicinal chemistry, structural and biochemical data for small molecule drug discovery.
Walter Rocchia, Eng. Ph.D and co-founder, is an electronic engineer by training, Walter is a Team Leader in Computational Chemistry at IIT, with solid experience in software development. During his postdoc at the Columbia University with Prof. Barry Honig, he developed the latest version of the software Delphi, worldwide utilized for continuum electrostatic calculations.
Andrea Spitaleri, Chairman of the board and and co-founder, is a Chemist by training with extensive experience in computational chemistry in academia and industry, with a Ph.D in Chemistry. He has routinely combined computational simulations with experimental observations coming from X-ray and NMR. Andrea worked at EPFL, University of Sheffield with Prof. Hunter, San Raffaele Hospital, and AstraZeneca, UK. Currently, he is a postdoc in Computational Chemistry at IIT and Principal Investigator of AIRC project.
Giuseppina La Sala, Ph.D in Computational Chemistry at IIT.
Luca Mollica, Ph.D, postdoc in Computational Chemistry at IIT
Francesca Spyrakis, Ph.D, postdoc at Università degli studi di Modena e Reggio Emilia.